Soleno Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Soleno Therapeutics kazanç ve gelirinin sırasıyla yıllık 66.8% ve 77% oranında artması tahmin edilirken, EPS'nin yıllık 58.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

66.8%

Kazanç büyüme oranı

58.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	77.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BST:6XC1 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2024	37	-18	N/A	N/A	2
12/31/2023	N/A	-32	N/A	N/A	2
12/31/2022	N/A	-28	N/A	N/A	2
6/30/2022	N/A	-23	-23	-23	N/A
3/31/2022	N/A	-28	-27	-27	N/A
12/31/2021	N/A	-31	-28	-28	N/A
9/30/2021	N/A	-31	-28	-28	N/A
6/30/2021	N/A	-31	-29	-29	N/A
3/31/2021	N/A	-28	-27	-27	N/A
12/31/2020	N/A	-25	-25	-25	N/A
9/30/2020	N/A	-36	-23	-23	N/A
6/30/2020	N/A	-27	-22	-22	N/A
3/31/2020	N/A	-30	-19	-19	N/A
12/31/2019	N/A	-31	-17	-17	N/A
9/30/2019	N/A	-16	-16	-16	N/A
6/30/2019	N/A	-19	-14	-14	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-12	-12	-12	N/A
9/30/2018	N/A	-16	-11	-11	N/A
6/30/2018	N/A	-17	-10	-10	N/A
3/31/2018	N/A	-13	-10	-10	N/A
12/31/2017	N/A	-12	-10	-10	N/A
9/30/2017	N/A	-13	-10	-10	N/A
6/30/2017	0	-11	-11	-11	N/A
3/31/2017	0	-9	-12	-12	N/A
12/31/2016	N/A	-10	-14	-13	N/A
9/30/2016	0	-8	-14	-14	N/A
6/30/2016	0	-10	-15	-14	N/A
3/31/2016	1	-7	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	0	-20	N/A	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 6XC1 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 6XC1 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 6XC1 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 6XC1 gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: 6XC1 gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 6XC1 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Soleno Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

New 90-day low: €1.14

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.85

New 90-day high: €1.70

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.35

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin